MRTX - It's Time To Buy Mirati Therapeutics Stock

• For a while at least. The last time completed a set of 37 priors over the most recent 5 years which produced 33 (89%) winners.
• Including their 4 losers, that netted profits at an annual rate of +375% during the more than 3 ½ years of capital (and time) investment required.
• Stock buys were signaled by Market-Maker forecasts like those of today. Signals offering upside price gains of +16.5%, when actual gains of +25% (net of losses) were achieved.
• The previously involved “whiles” averaged 36 (market days) each, or shy of 2 months of calendar days, as dictated by a time-efficient portfolio management discipline.
• Which is what it takes to get equity investment capital to produce +375% rates rather than Index-ETF rates of under +10% rates normally (or under +20% in exceptional times).

For further details see: